Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
2013 valuation was based on opioid potential. Company had to completely re-engineer itself. Not apples to apples comparison. Elite sold off their opioid like that would have brought in stable and growing revenue over the years.
Primary fallibility with DCF is inability to account for risk to Elite’s main source of revenue in partnering with a new distributor. Relaunch and penetration in a crowded market is only going to lead to a longer ramp they had with Lannett. Hoping they don’t create sales force of their own for Adderall. If Lannett pulls plug before Elite is ready, company will have to tap into those cash reserves to stay afloat.
Starts with “M” and ends with “anagement”.
Myriad of reasons why stock hasn’t moved. For starters, any positive news is offset by risks, especially when the magnitude is unknown. What Elite has been plagued with for years is uncertainty. This is far worse than when bad news is communicated with to bad shareholders. This holds for any publicly traded company. Shareholders care about future earnings and profitability. When almost all of Elite’s eggs are in one basket and CEO communicates to shareholders that that basket may no longer exist, there will of course be pressure on the stock price. We know CEO is working on it, but we don’t know with whom, when, financial impact, ramp up and launch timing, etc. There is a significant amount of risk that shareholders are in the dark on. This is one of the main reasons why the stock doesn’t move - uncertainty.
This is what IR is for - to act as voice for management. IR doesn’t like to field emails from individual shareholders let alone CEO.
IR has much smaller market than XR.
2-year agreement with either party being able to terminate the agreement doesn’t mean it’s locked in for 2 years. Just means Lannett isn’t quite ready yet to pull those strings, but will be soon and are well on their way.
Concerta rather than Vyvanse. Vyvanse can’t have generic until Aug 2023.
He can’t simply dump Lannett. Our back is against the wall. It has taken 2 years to have our Adderall revenue at these levels. That new partner will most likely have to start from scratch, which was incredibly painful for many months. It takes 6-9 months for the profit splits to start coming in. This is no easy risk free transition. This situation could end up badly if we are expecting a Vyvanse generic and get something like Loxapine and Lannett pulls the plug.
A large ownership by the CEO is not a sign of future success.
Here’s one example of many. AMSC released awful news. CEO bought a crapload of stock on the way down from $300+/share several years ago as it fell to about $40/share. Stock is now $7 and change.
Ownership of one person doesn’t instill confidence. Ownership of many might. Where are all the directors buying stock?
Riiiiight
All good comments. I think Sungen still has their hands in this cookie jar. Too much potential on this one compared to small antibiotic if in fact it is the larger CNS.
I just figured it was another one filed with Sungen. Inconsistent relationships lead to challenging baggage.
The move to internal marketing would be absolutely devastating to revenue. It never seems to work out for smaller companies. When we become more stable we can take that risk.
Well, don’t forget the CEO is paid 50% in cash and has been for a while. He also gets paid from side deals with Mikah. How did you score getting included in those? Asking for a friend.
They did many years ago
Yes, exactly. We know about the antibiotic. Not sure we have any insight on the other.
2 have already been submitted
Pending any approvals, next cc will be in late June to wrap up and review the fiscal year ending March. This is always longest period of silence…
Other than Covid impact on studies for new filings
International expansion of current Adderall ER & IR could be huge. Looking to see launch with Dexcel soon to kickstart that or if any other countries are in the cards.
It’s not listed in subsequent events and took place within the quarter.
No subsequent events so nothing has happened with Dexcel partnership yet.
About 9.M rev Q3
Our last one couldn’t account for basic contractual revenue correctly. Anything is a step up.
If side deals with CEO were a show of confidence to investors, the stock price would be through the roof.
Posters have been saying they same thing on the board for the last 10 years…
Big whoop. I consulted for a Fortune 5 and can say it in less than 100 paragraphs.
No they don’t. They are only running multiple shifts due to Covid spacing. Plenty of building capacity to run more shifts. Hopefully we’ll see some demand for that soon.
And Nasrat sold off our entire line of opioids except for the one the FDA won’t approve.
Maybe we’ll hear about another Valentine’s Day dinner between Nasrat and Sungen since it’s the day after the holiday.
Shorts eaten. CC day early followed by crappy news day after cc?
I think it will be the next day. SEC filing isn’t due until 15th with cc to follow the subsequent morning. PR should be out by Friday.
Spot on. Mediocrity is the out of reach goal with setbacks often the prize the shareholders with a heavy dose of dilution early in the process. The nothingness from these calls is just pouring salt on an open wound.
Trials need to be rerun and resubmitted to FDA for approval. SequestOx is not under active review.
Elite and LCI are in a race to the bottom today.
I interpreted that as antibiotic with Sungen, but only if Sungen moved with their response. Their are no other products under review nearing approval that have been communicated.
Extremely unlikely. Concerta has far fewer competitors than Adderall ER & IR. Lannett has also delayed shipments in the past impacting Elite, while they burn down inventory.
That’s because the share price kept breaking through the contracted floor.
Nice cut and paste. Forgot the big dilution part and law of small numbers.
Significant revenue rising vs a small number, is still small $. This company’s outstanding shares have ballooned to 1 Billion+ with full dilution under this CEO.